PubRank

T C Hamilton

Author PubWeight™ 164.27‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A 1992 5.24
2 Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res 1985 5.09
3 Comparison of the effects of BRL 34915 and verapamil on electrical and mechanical activity in rat portal vein. Br J Pharmacol 1986 4.75
4 High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A 1992 3.22
5 Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res 1983 2.90
6 Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 1987 2.67
7 Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 1984 2.24
8 Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 1996 2.17
9 Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 1985 1.86
10 Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. J Natl Cancer Inst 1992 1.82
11 BRL 34915, a novel antihypertensive agent: comparison of effects on blood pressure and other haemodynamic parameters with those of nifedipine in animal models. J Cardiovasc Pharmacol 1986 1.79
12 AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells. Cancer Res 1998 1.61
13 Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. J Natl Cancer Inst 1992 1.61
14 Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol 2000 1.58
15 Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res 1988 1.55
16 Inhibition by glibenclamide of the vasorelaxant action of cromakalim in the rat. Br J Pharmacol 1989 1.52
17 Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 1987 1.50
18 The biology of ovarian cancer. Semin Oncol 1998 1.46
19 Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br J Cancer 2005 1.42
20 Genes amplified and overexpressed in human multidrug-resistant cell lines. Cancer Res 1988 1.42
21 Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches. Semin Oncol 1984 1.41
22 Ovarian cancer biology. Semin Oncol 1991 1.40
23 Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res 1997 1.39
24 The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 1998 1.39
25 Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res 1984 1.35
26 Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int J Cancer 1990 1.35
27 The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res 2000 1.27
28 Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res 1984 1.25
29 Quantitative evidence for protein denaturation as the cause of thermal death. Nature 1971 1.24
30 Identification of two candidate tumor suppressor genes on chromosome 17p13.3. Cancer Res 1996 1.21
31 Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res 1995 1.18
32 Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. Cancer Res 1994 1.14
33 Anti-transferrin receptor antibody linked to Pseudomonas exotoxin as a model immunotoxin in human ovarian carcinoma cell lines. Cancer Res 1985 1.12
34 Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. J Natl Cancer Inst 1989 1.11
35 Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res 1993 1.11
36 Autonomy of the epithelial phenotype in human ovarian surface epithelium: changes with neoplastic progression and with a family history of ovarian cancer. Int J Cancer 1996 1.11
37 Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res 1995 1.11
38 Potassium channel activator drugs: mechanism of action, pharmacological properties, and therapeutic potential. Med Res Rev 1992 1.11
39 The biology of ovarian cancer development. Cancer 1993 1.10
40 Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol 1996 1.07
41 Mechanisms of drug resistance in ovarian cancer. Cancer 1993 1.06
42 Disabled-2 mediates c-Fos suppression and the cell growth regulatory activity of retinoic acid in embryonic carcinoma cells. J Biol Chem 2001 1.05
43 Clinical studies of reversal of drug resistance based on glutathione. Chem Biol Interact 1998 1.03
44 Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. Cancer Res 1994 1.03
45 Spontaneous transformation of rat ovarian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexity. Cancer Res 1994 1.03
46 Expression of insulin-like growth factor I, its binding proteins, and its receptor in ovarian cancer. Cancer Res 1991 1.03
47 Adriamycin accumulation and metabolism in adriamycin-sensitive and -resistant human ovarian cancer cell lines. Biochem Pharmacol 1986 1.02
48 Identification of a zinc-finger gene at 6q25: a chromosomal region implicated in development of many solid tumors. Oncogene 1997 1.02
49 Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochem Pharmacol 1988 1.02
50 Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 1999 1.02
51 Mechanisms of resistance to cisplatin and alkylating agents. Cancer Treat Res 1989 1.01
52 Use of a surrogate marker (human secreted alkaline phosphatase) to monitor in vivo tumor growth and anticancer drug efficacy in ovarian cancer xenografts. Gynecol Oncol 2000 1.01
53 Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione. Biochem Pharmacol 1987 1.00
54 Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer 1993 1.00
55 Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo. Cancer Res 1994 0.99
56 Identification of a gene containing zinc-finger motifs based on lost expression in malignantly transformed rat ovarian surface epithelial cells. Cancer Res 1997 0.99
57 A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines. Eur J Cancer 1993 0.98
58 Cross-resistance, cisplatin accumulation, and platinum-DNA adduct formation and removal in cisplatin-sensitive and -resistant human hepatoma cell lines. Exp Cell Res 1996 0.98
59 Androgen and oestrogen binding in cytosols of human ovarian tumours. J Endocrinol 1981 0.96
60 Synthesis and antihypertensive activity of 4-(cyclic amido)-2H-1-benzopyrans. J Med Chem 1986 0.96
61 Synthesis and antihypertensive activity of 4-(substituted-carbonylamino)-2H-1-benzopyrans. J Med Chem 1990 0.96
62 Comparative effects of K+ channel blockade on the vasorelaxant activity of cromakalim, pinacidil and nicorandil. Eur J Pharmacol 1988 0.95
63 Characterization of immunotoxins active against ovarian cancer cell lines. J Clin Invest 1985 0.95
64 Synthesis and antihypertensive activity of substituted trans-4-amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ols. J Med Chem 1983 0.95
65 Recent insights into platinum drug resistance in cancer. Drug Resist Updat 1998 0.95
66 Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat. Am J Obstet Gynecol 1996 0.95
67 Glutathione and drug resistance. Cancer Invest 1996 0.95
68 Serial determinations of glutathione levels and glutathione-related enzyme activities in human tumor cells in vitro. Biochem Pharmacol 1986 0.94
69 Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems. Pharmacol Ther 1990 0.93
70 Estrogen and anti-estrogen effects on the growth of human epithelial ovarian cancer in vitro. Obstet Gynecol 1989 0.93
71 Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem Pharmacol 1994 0.93
72 Expression of two mucin antigens in cultured human ovarian surface epithelium: influence of a family history of ovarian cancer. Am J Obstet Gynecol 1995 0.93
73 Modification of the vascular response to isoprenaline by cholinomimetic drugs. Br J Pharmacol 1971 0.92
74 Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz. J Clin Invest 1996 0.92
75 Disassociation of MAPK activation and c-Fos expression in F9 embryonic carcinoma cells following retinoic acid-induced endoderm differentiation. J Biol Chem 2001 0.90
76 Talc in normal and malignant ovarian tissue. Lancet 1979 0.90
77 Cromakalim, a potassium channel activator: a comparison of its cardiovascular haemodynamic profile and tissue specificity with those of pinacidil and nicorandil. J Cardiovasc Pharmacol 1988 0.89
78 Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells. Mol Cell Endocrinol 1994 0.88
79 Multidrug resistance in ovarian cancer. Cancer 1987 0.88
80 Synthesis and antihypertensive activity of 6,7-disubstituted trans-4-amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ols. J Med Chem 1984 0.88
81 Retroviral-like sequences specifically expressed in the rat ovary detect genetic differences between normal and transformed rat ovarian surface epithelial cells. Endocrinology 1995 0.87
82 Antihypertensive and haemodynamic properties of the potassium channel activating (-) enantiomer of cromakalim in animal models. Arzneimittelforschung 1991 0.87
83 Modulation of induced resistance to adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate. Cancer Chemother Pharmacol 1988 0.86
84 Effects of dopamine on the conductance of perfused vascular beds of the chloralosed cat. Br J Pharmacol 1972 0.86
85 Quantitative analysis of ciliary and contractile responses during habituation training in Spirostomum ambiguum. Behav Biol 1974 0.86
86 Studies on the cardiovascular effects of pindolol in DOCA/saline hypertensive rats. Br J Pharmacol 1977 0.85
87 Mechanisms of cross-resistance between radiation and antineoplastic drugs. NCI Monogr 1988 0.85
88 Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment. Cancer Res 1993 0.85
89 Diminishing hypotensive effect of increasing doses of pindolol in DOCA/saline hypertensive rats. Br J Pharmacol 1978 0.85
90 Oestrogen receptor-like binding in the surface germinal epithelium of the rat ovary. J Endocrinol 1982 0.85
91 Telomeric instability and reduced proliferative potential in ovarian surface epithelial cells from women with a family history of ovarian cancer. Gynecol Oncol 1999 0.85
92 In vitro interactions between platinum analogues in human ovarian-carcinoma cell lines. Cancer Chemother Pharmacol 1992 0.84
93 A method for the continuous recording of peripheral vascular conductance. J Pharm Pharmacol 1971 0.84
94 Adoptive cellular immunotherapy of human ovarian carcinoma xenografts in nude mice. Cancer Res 1986 0.84
95 Effect of intracerebroventricular 5,6-dihydroxytryptamine on blood pressure of spontaneously hypertensive rats. Eur J Pharmacol 1976 0.84
96 Motor dysfunction in a photothrombotic focal ischaemia model. Behav Brain Res 1996 0.83
97 Effects of BRL 38227 on neurally-mediated responses in the guinea-pig isolated bronchus. Br J Pharmacol 1992 0.83
98 beta-Adrenoceptor blocking drugs and hypertension. Gen Pharmacol 1979 0.83
99 Effects of talc on the rat ovary. Br J Exp Pathol 1984 0.82
100 Antitumor activity of an immunotoxin in a nude mouse model of human ovarian cancer. Cancer Res 1987 0.82
101 Vascular endothelial growth factor in ovarian cancer. Curr Oncol Rep 1999 0.82
102 LOT1 is a growth suppressor gene down-regulated by the epidermal growth factor receptor ligands and encodes a nuclear zinc-finger protein. Oncogene 1999 0.82
103 Summary of symposium: Biology and therapy of ovarian cancer. Semin Oncol 1991 0.82
104 The role of glutathione in drug resistance. Cancer Treat Rev 1990 0.82
105 Ovarian epithelial cell lineage-specific gene expression using the promoter of a retrovirus-like element. Cancer Res 2001 0.82
106 Early ovarian cancer: a review of its genetic and biologic factors, detection, and treatment. Curr Probl Cancer 1996 0.81
107 Ribonucleic acid in plasma from normal adults and multiple myeloma patients. Clin Chem 1979 0.81
108 Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. Clin Cancer Res 1996 0.81
109 Involvement of central alpha 2-adrenoceptors in the mediation of clonidine-induced hypotension in the cat. J Pharm Pharmacol 1980 0.80
110 The effects of some phosphodiesterase inhibitors on the conductance of the perfused vascular beds of the chloralosed cat. Br J Pharmacol 1972 0.80
111 Effects of synthetic peptides and protease inhibitors on the interaction of a human ovarian cancer cell line (NIH:OVCAR-3) with a reconstituted basement membrane (Matrigel). Invasion Metastasis 1991 0.80
112 Collateral susceptibility of adriamycin-, melphalan- and cisplatin-resistant human ovarian tumor cells to bleomycin. Jpn J Cancer Res 1986 0.80
113 A comparison of the cardiovascular and sedative actions of the alpha-adrenoceptor agonists, FLA-136 and clonidine, in the rat. Br J Pharmacol 1982 0.79
114 Bufuralol, a new beta-adrenoceptor blocking agent. Experientia 1975 0.79
115 Potentiation of cisplatin cytotoxicity in human ovarian carcinoma cell lines by trifluoperazine, a calmodulin inhibitor. Gynecol Oncol 1992 0.79
116 Increased DT-diaphorase expression and cross-resistance to mitomycin C in a series of cisplatin-resistant human ovarian cancer cell lines. Biochem Pharmacol 1996 0.79
117 The chemopreventive agent oltipraz stimulates repair of damaged DNA. Cancer Res 1997 0.79
118 Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines. Int J Cancer 1991 0.79
119 Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO. Cancer Res 1995 0.79
120 Comparison of the cardiovascular effects of the novel 5-HT(1B/1D) receptor agonist, SB 209509 (VML251), and sumatriptan in dogs. J Cardiovasc Pharmacol 1997 0.78
121 Induction of progesterone receptor with 17 beta-estradiol in human ovarian cancer. J Clin Endocrinol Metab 1984 0.78
122 Presynaptic dopamine receptors mediate the inhibitory action of dopamine agonists on stimulation-evoked pressor responses in the rat. J Auton Pharmacol 1982 0.78
123 Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer. Drug Metab Dispos 1995 0.78
124 Plasma prolactin concentrations in hypertensive rats. J Pharm Pharmacol 1979 0.78
125 Bufuralol, a new beta-adrenoceptor blocking agent in a series of benzofuran-2-ethanolamines. Part 2: pharmacology. Arzneimittelforschung 1977 0.78
126 Comparison of the anti-hypertensive response to beta-adrenoceptor blocking drugs in intact and adrenal-demedullated spontaneously hypertensive rats. Br J Pharmacol 1980 0.78
127 Genome scanning detects amplification of the cathepsin B gene (CtsB) in transformed rat ovarian surface epithelial cells. J Soc Gynecol Investig 1999 0.77
128 Gracile nucleus absent in adult opossums after leg removal in infancy. Brain Res 1972 0.77
129 Effects of isradipine, an L-type calcium channel blocker on permanent and transient focal cerebral ischemia in spontaneously hypertensive rats. Exp Neurol 1997 0.77
130 Growth inhibition and cytotoxicity induced by Bowman-Birk inhibitor concentrate in cisplatin-resistant human ovarian cancer cells. Nutr Cancer 1998 0.77
131 Neuroprotective effect of recombinant neutrophil inhibitory factor in transient focal cerebral ischaemia in the rat. Neurodegeneration 1996 0.77
132 Influence of anti-hypertensive drug treatment on vascular reactivity in spontaneously hypertensive rats. Br J Pharmacol 1975 0.77
133 Cellular glutathione levels and sensitivity to radiation and antineoplastic agents in human ovarian cancer. Prog Clin Biol Res 1988 0.77
134 Transformation of rat ovarian epithelial and Rat-1 fibroblast cell lines by RAST24 does not influence cisplatin sensitivity. Cancer Res 1993 0.77
135 Growth regulation of ovarian cancer. Hematol Oncol Clin North Am 1992 0.77
136 Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action. J Clin Invest 1993 0.77
137 The role of molecular biology in understanding ovarian cancer initiation and progression. Int J Gynecol Cancer 2001 0.77
138 Identification of zinc finger mRNAs using domain-specific differential display. Anal Biochem 1996 0.77
139 Differential expression of c-fos, Hsp70 and Hsp27 after photothrombotic injury in the rat brain. Brain Res Mol Brain Res 1997 0.77
140 Hypotensive responses following oral adminstration of beta-adrenoceptor blocking drugs to the conscious cat. Eur J Pharmacol 1976 0.76
141 Decreased cisplatin damage-dependent DNA synthesis in cellular extracts of mismatch repair deficient cells. Biochem Pharmacol 1999 0.76
142 [Epithelial ovarian cancer (advanced stage): consensus conference (1998)]. Gynecol Obstet Fertil 2000 0.76
143 Somatotopic organization related to nuclear morphology in the cuneate-gracile complex of opossums Didelphis marsupialis virginiana. Brain Res 1973 0.76
144 Evaluation of in vitro drug screening leads using experimental models of human ovarian cancer. Invest New Drugs 1992 0.76
145 Involvement of the adrenal glands in the hypotensive response to bromocriptine in spontaneously hypertensive rats. Br J Pharmacol 1981 0.75
146 Re: Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1999 0.75
147 Cyclic nucleotides and central cardiovascular control in the cat [proceedings]. Br J Pharmacol 1978 0.75
148 Failure of isradipine to reduce infarct size in mouse, gerbil, and rat models of cerebral ischemia. Stroke 1995 0.75
149 Prolonged effects of p-chlorophenylalanine on the blood pressure of conscious normotensive and DOCA/saline hypertensive rats. Br J Pharmacol 1976 0.75
150 Clinical reversal of drug resistance in ovarian cancer. Gynecol Oncol 1993 0.75
151 The demonstration of the migration of talc from the vagina and posterior uterus to the ovary in the rat. Environ Res 1986 0.75
152 K+ channel activators, acute glucose tolerance and glibenclamide-induced hypoglycaemia in the hypertensive rat. Eur J Pharmacol 1994 0.75
153 Activity of tricyclic nucleoside 5'-phosphate in model systems of human ovarian cancer. Invest New Drugs 1986 0.75
154 Measurements of contraction latencies to mechanical and electrical stimulation of the protozoan, Spirostomum ambiguum. J Cell Physiol 1977 0.75
155 Serum CA 125 and survival of mice inoculated with ovarian carcinoma and treated with antiestrogen, estrogen, or progestin. Gynecol Oncol 1987 0.75
156 New non-cytotoxic approaches to ovarian cancer. Ann Oncol 1999 0.75
157 Advanced ovarian cancer. Drug resistance, supportive care and dose intensity. Ann Oncol 1993 0.75
158 Clinical evaluation of immunochemical assay of lactate dehydrogenase isoenzyme 1 in early detection of acute myocardial infarction. Clin Chem 1982 0.75
159 Comparison of the effects of nabumetone, a new anti-inflammatory drug, and indomethacin on arachidonic acid-induced hypotension in the rat. J Pharm Pharmacol 1983 0.75
160 Electron microbeam analysis of calcium distribution in the ciliated protozoan, Spirostomum ambiguum. J Cell Physiol 1977 0.75
161 Neuronally-induced vasodilator response in the splanchnic region of the chloralosed cat. J Pharm Pharmacol 1975 0.75
162 The effects of SB 206284A, a novel neuronal calcium-channel antagonist, in models of cerebral ischemia. J Cereb Blood Flow Metab 1997 0.75
163 Evidence for the involvement of alpha-adrenoceptor blockade in the antihypertensive action of diazoxide in the renal hypertensive rat. Eur J Pharmacol 1975 0.75
164 Hyperaemic responses in two vascular beds of the anaesthetised cat. Arch Int Pharmacodyn Ther 1976 0.75
165 Cyclic nucleotides and central cardiovascular control in the conscious cat. Eur J Pharmacol 1980 0.75
166 Determinants of cisplatin sensitivity in normal versus spontaneously transformed rat ovarian surface epithelial cells. Gynecol Oncol 1995 0.75
167 Modulation of drug resistance in human ovarian cancer: experimental results and clinical applications. Prog Clin Biol Res 1986 0.75
168 Modulation of glutathione and related enzymes in reversal of resistance to anticancer drugs. Hematol Oncol Clin North Am 1995 0.75
169 Involvement of presynaptic dopamine receptors in the antihypertensive response to 2-NN-dimethylamino-5,6-dihydroxy-1,2,3,4,-tetrahydronaphthalene (M-7). J Pharm Pharmacol 1982 0.75
170 Relative lack of cardiotoxicity of paroxetine in animal models. Acta Psychiatr Scand Suppl 1989 0.75
171 Preclinical evaluation of aclacinomycin A for the intraperitoneal treatment of human ovarian carcinoma. Cancer Chemother Pharmacol 1986 0.75
172 Comparison of the vasodilator activity of acetylcholine, cholinomimetics and other vasodilators in two vascular beds of the cat. Eur J Pharmacol 1974 0.75
173 Intrinsic sympathomimetic activity of beta-adrenoceptor blocking drugs at cardiac and vascular beta-adrenoceptors. Life Sci 1978 0.75
174 Comparison of some effects of paroxetine with amitriptyline on the cardiovascular system in animals. Arzneimittelforschung 1986 0.75